Mode-of-Action Archives - Page 2 of 2 - Willingsford Healthcare

About
How to Use
- How to use Amicapsil
- How to use SertaSil
Technology
- MPPT – micropore particle technology
SCI
Wounds
- Amicapsil – Humans
- SertaSil – Animals
Dermatology
- Aprobaxil – Humans
- Adinasil – Animals
Sustainability
- Sustainability
- Antimicrobials and Climate Change
Info
Shop

About
How to Use
- How to use Amicapsil
- How to use SertaSil
Technology
- MPPT – micropore particle technology
SCI
Wounds
- Amicapsil – Humans
- SertaSil – Animals
Dermatology
- Aprobaxil – Humans
- Adinasil – Animals
Sustainability
- Sustainability
- Antimicrobials and Climate Change
Info
Shop

Two clinical studies confirm Amicapsil’s effect on pressure injuries

Two clinical studies confirm
Amicapsil’s effect on pressure injuries

Download Publication

Both studies find 100% closure rates
for acute and chronic pressure injuries

Slider-web-AMR

See video, where Lady-Marie from UK Spinal Injuries Association describes how Amicapsil has treated her pressure injuries

Slider-web-60%

MPPT removes wound infections 60%
quicker than antibiotics and antiseptics.

Effective on resistant infections and does not contribute to AMR.

Slider-web-passive-immunotherapy

Passive Immunotherapy

acting via the skin and wound microbiome without the use of antimicrobials.

Slider-web-pain-etc

Amicapsil and Amicapsil-SCI

Effective wound treatment in immunocompetent and immunocompromised persons

Effective on antibiotic and antiseptic resistant wound infections.
Effective in immunocompetent and immunocompromised persons.

Slider-web-1

Less Scarring

“Where I have used Acapsil the scarring is flat, whereas the older scars are hypertrophic.” Patient ST

“Where I have used Acapsil the scarring is flat against the surrounding skin, whereas the older scars are bulging / hypertrophic.” Patient ST

“Where I have used Aprobaxil the scarring is flat against the surrounding skin, whereas the older scars are bulging / hypertrophic.” Patient ST

Slider-web-1 – NH

“Amicapsil changed my life.”

“From 4 weeks of absolute hell – to being pain-free, getting a full night’s sleep and back to normal at work.”

“From 4 weeks of absolute hell, in pain 24 hours a day, struggling at work – to being pain-free, getting a full night’s sleep and back to normal at work.”

NH ( patient)

Slider-web-15

69.5% Savings

Cost-effectiveness determined in NHS Clinical Audit

Slider-web-hypoallergenic

Hypoallergenic

Only natural ingredients

Slider-web-FDA

FDA concluded in 2022:

Standard wound products, including antimicrobials, are ineffective.

US FDA 2016

Verma et al. (2022)

Slider-web-AMR

Amicapsil-SCI

Effective treatment of wounds and pressure ulcers in SCI-persons and in controlling soft tissue infection caused by osteomyelitis

Effective treatment of wounds and pressure ulcers in SCI-persons and in controlling soft tissue infection caused by osteomyelitis.

Slider-web-AMR

Antibiotics reduce the amount of carbon that can be stored in soil. This directly increases CO2 in the atmosphere and contributes to climate change.
One course of antibiotic release the same amount of carbon as a car driving around Earth 1.47 times.

Slider-web-No-brainer

“For me, this Amicapsil open air method is a no brainer. It is easier, no fuss, and obviously cheaper than these expensive dressings.”

VH (patient)

Slider-web-Pollution

MPPT is environmentally sustainable:
it is biologically recyclable and does not require the use of chemicals, plastics or antimicrobials.

Does Amicapsil contribute to the creation of antibiotic resistant bacterial strains?

No. MPPT is not an antibiotic and it does not have any direct antimicrobial action – it does not kill the bacteria. Bacteria have two

Can wounds with antibiotic resistant infections benefit from MPPT?

Yes. MPPT has assisted in clearing up antibiotic resistant infections. MPPT is not an antibiotic but instead allows the body’s own immune system access to

Willingsford Limited

NFEC, Rushington Business Park

Chapel Lane, Totton

Southampton SO40 9LA, United Kingdom

Phone: +44(0)23 8081 2325

E-mail: contact @ willingsford.com

News

Name

Message